A single dose of Evusheld appears effective at preventing COVID-19 infection, without notable safety concerns, in patients at risk for infection or vaccine nonresponse, according to data published in the New England Journal of Medicine.
“AZD7442 has been shown to neutralize SARS-CoV-2 and its variants of concern in vitro and has prophylactic and therapeutic effects in nonhuman primates,” Myron J. Levin, MD, of the University of Colorado School of Medicine in Aurora, and co-authors wrote. “In a phase 1 study, intramuscular administration of 300 mg of AZD7442 provided higher